{"id":778205,"date":"2025-12-06T13:35:01","date_gmt":"2025-12-06T13:35:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=778205"},"modified":"2025-12-06T13:35:01","modified_gmt":"2025-12-06T13:35:01","slug":"ngs-sample-preparation-market-growth-outlook-competitive-landscape-future-business-opportunities","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/ngs-sample-preparation-market-growth-outlook-competitive-landscape-future-business-opportunities_778205.html","title":{"rendered":"NGS Sample Preparation Market: Growth Outlook, Competitive Landscape &#038; Future Business Opportunities"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/12\/1764939679.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"NGS Sample Preparation Market: Growth Outlook, Competitive Landscape &amp; Future Business Opportunities\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/12\/1764939679.jpg\" alt=\"NGS Sample Preparation Market: Growth Outlook, Competitive Landscape &amp; Future Business Opportunities\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Prominent players in the NGS sample preparation market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), PerkinElmer Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US)<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Browse 299 market data Tables and 47 Figures spread through 301 Pages and in-depth TOC on &#8220;NGS Sample Preparation Market by Product (Reagents &#038; Consumables, Workstations), Workflow (Library Prep, Target Enrichment), Sample Type (DNA), Application (Diagnostics, Drug Discovery), Method (Microfluidic, Automated), End User- Global Forecast to 2028<\/div>\n<p style=\"text-align: justify;\">The global Next-Generation Sequencing (NGS) sample preparation market continues to experience robust growth, driven by efficiency gains in sequencing workflows, rising adoption in clinical applications, and strategic collaboration among industry leaders. In 2022, the market was valued at <strong>USD 1.9 billion<\/strong>, and it is projected to reach <strong>USD 4.0 billion by 2028<\/strong>, expanding at a strong <strong>CAGR of 13.4%<\/strong>. While multiple drivers are shaping this momentum, ethical considerations surrounding genomic data privacy remain a notable restraint.<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" title=\"\" href=\"https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=69735098\">Download an Illustrative overview: <\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Market Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">NGS has moved from a specialized research technology to a scalable, clinically relevant tool across oncology, infectious disease monitoring, reproductive health, and precision medicine. Sample preparation&mdash;one of the most critical stages in the sequencing workflow&mdash;has seen rapid technological advancements, including <strong>automation, enzymatic fragmentation, and improved genotyping protocols<\/strong>. These innovations reduce manual handling time, improve efficiency, and enable high-throughput sequencing environments to scale.<\/p>\n<p style=\"text-align: justify;\">The market&rsquo;s appeal is further backed by increasing activity in collaborative R&amp;D, deeper penetration of sequencing-based diagnostics, and higher government and institutional investment.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Factors Driving Market<\/strong><strong>1. NGS as a Substitute for PCR<\/strong><\/p>\n<p style=\"text-align: justify;\">NGS has increasingly emerged as a superior alternative to traditional PCR-based testing due to:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Ability to detect complete genomic profiles rather than isolated genetic fragments<\/li>\n<li>Strength in precision medicine and pathogen surveillance<\/li>\n<li>Improved accuracy in mutation detection<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">As clinical laboratories shift toward more comprehensive genetic insights, demand for more efficient sample prep protocols continues to accelerate.<\/p>\n<p style=\"text-align: justify;\"><strong>2. Greater Efficiency of Genotyping and Preparation Protocols<\/strong><\/p>\n<p style=\"text-align: justify;\">Human whole genome sequencing has become a cornerstone in infectious disease outbreak management. Over the past decade, advanced protocols for <strong>genotyping<\/strong> have set new standards, particularly in bacterial outbreak investigations. Key aspects driving efficiency:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Higher resolution sequencing capability<\/strong><\/li>\n<li><strong>Reduced hands-on time<\/strong> through enzymatic fragmentation<\/li>\n<li><strong>Ability to process small DNA quantities<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">While Illumina remains the most widely used platform, presence of emerging protocols from <strong>Thermo Fisher<\/strong> and <strong>PerkinElmer<\/strong> broadens the competitive landscape and supports diverse research environments.<\/p>\n<p style=\"text-align: justify;\"><strong>3. Rising Automation in NGS Workflows<\/strong><\/p>\n<p style=\"text-align: justify;\">Automated workstations have significantly enhanced throughput, minimized variability, and reduced operational costs across clinical labs and sequencing centers. These efficiencies position automation-enabled sample preparation as a key growth driver in the market.<\/p>\n<p style=\"text-align: justify;\"><strong>4. Strategic Partnerships and Collaborations<\/strong><\/p>\n<p style=\"text-align: justify;\">Major market stakeholders&mdash;Illumina, Thermo Fisher Scientific, and PerkinElmer&mdash;are partnering with pharmaceutical companies, research labs, hospitals, and academic institutes. These collaborations fuel new product development, align sequencing workflows with clinical needs, and expand adoption among end users.<\/p>\n<p style=\"text-align: justify;\"><strong>5. Increasing Applications in Disease Diagnostics<\/strong><\/p>\n<p style=\"text-align: justify;\">The healthcare sector increasingly leverages NGS for:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Early cancer detection<\/li>\n<li>Identification of infectious diseases<\/li>\n<li>Precision medicine<\/li>\n<li>Monitoring monogenetic disorders<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">As routine diagnostics shift toward genomic data, demand for efficient prep kits, consumables, and automated systems is rapidly increasing.<\/p>\n<p style=\"text-align: justify;\"><strong>Market Restraints<\/strong><strong>Presence of Alternative Technologies<\/strong><\/p>\n<p style=\"text-align: justify;\">Although NGS adoption is rising, legacy solutions such as Sanger sequencing, PCR, antigen tests, and serology continue to hold market share, especially in cost-sensitive regions and target applications. Their familiarity and lower pricing remain competitive barriers in specific segments.<\/p>\n<p style=\"text-align: justify;\"><strong>Ethical and Data Privacy Challenges<\/strong><\/p>\n<p style=\"text-align: justify;\">Expanding genomic testing in population-level initiatives has raised concerns regarding:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Unintended data disclosure<\/li>\n<li>Potential commercialization of genomic datasets<\/li>\n<li>Consent mechanisms and cross-border genomic governance<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Non-invasive prenatal testing (NIPT), in particular, faces ethical concerns including <strong>sex selection, decision-making complexities, and implications for disability rights<\/strong>. These challenges may slow adoption in certain markets unless regulatory clarity and data safety frameworks improve.<\/p>\n<p style=\"text-align: justify;\"><strong>Segment Insights<\/strong><strong>By Sample Type: Dominance of DNA<\/strong><\/p>\n<p style=\"text-align: justify;\">DNA-based analysis accounted for the largest share in 2022, driven by:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Increasing global cancer prevalence<\/li>\n<li>Intensifying genomic research<\/li>\n<li>Growing precision medicine initiatives<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Demand for DNA sample prep is expected to remain strong throughout the forecast period, with oncology-focused methods leading the charge.<\/p>\n<p style=\"text-align: justify;\"><strong>By Product &amp; Service: Workstations\/Instruments Lead<\/strong><\/p>\n<p style=\"text-align: justify;\">In 2022, <strong>workstation and instrument sales<\/strong> represented the largest revenue segment. Drivers include:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Rising need to automate high-throughput workflows<\/li>\n<li>Reducing prep time and operator dependence<\/li>\n<li>Enhanced reproducibility and process standardization<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Reagents and consumables also show strong recurring revenue potential, forming a significant profitability stream.<\/p>\n<p style=\"text-align: justify;\"><strong>By Application: Disease Diagnostics at the Frontline<\/strong><\/p>\n<p style=\"text-align: justify;\">The disease diagnostics segment generated the largest share of 2022 revenue. This growth is supported by:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Earlier cancer detection initiatives<\/li>\n<li>Sequencing-led infectious disease identification<\/li>\n<li>Precision therapeutic decisions<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">As healthcare systems shift toward genomic-led preventive strategies, clinical demand for NGS prep will continue to expand.<\/p>\n<p style=\"text-align: justify;\"><strong>Regional Market Outlook<\/strong><strong>North America: Largest Market Share<\/strong><\/p>\n<p style=\"text-align: justify;\">In 2022, North America led the global NGS sample preparation market. Growth is attributed to:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Supportive government and institutional sequencing initiatives<\/li>\n<li>Advanced genomic infrastructure<\/li>\n<li>Significant research funding<\/li>\n<li>Presence of leading service providers including <strong>Illumina (US), Thermo Fisher Scientific (US), and Agilent Technologies (US)<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The region&rsquo;s mature regulatory and reimbursement environment continues to favor adoption in both research and clinical segments.<\/p>\n<p style=\"text-align: justify;\"><strong>Emerging Market Opportunities<\/strong><\/p>\n<p style=\"text-align: justify;\">Looking ahead, vendors will benefit from:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Robust demand for <strong>automated sample prep systems<\/strong><\/li>\n<li>Expansion of sequencing-driven oncology solutions<\/li>\n<li>Continuous improvements in enzymatic fragmentation methods<\/li>\n<li>Strategic collaborations to accelerate product innovation<\/li>\n<li>Commercial traction from recurring consumable revenue<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Long-term growth will also be supported by stronger partnerships between genomic labs and pharmaceutical companies developing precision therapies.<\/p>\n<p style=\"text-align: justify;\"><strong>Conclusion<\/strong><\/p>\n<p style=\"text-align: justify;\">The NGS sample preparation market is positioned for sustained double-digit growth through 2028. Efficiency gains, clinical applications, and automation-led scalability are strengthening industry momentum. While ethical data-handling issues warrant continued discussion and governance, the market offers strong expansion opportunities across diagnostics, biotechnology, drug development, and sequencing services.<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" title=\"\" href=\"https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=69735098\">Request for Sample Pages:<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/marketsandmarkets.com_145966.html\" rel=\"nofollow\">MarketsandMarkets\u2122 Research Private Ltd.<\/a><br \/><strong>Contact Person:<\/strong> Mr. Rohan Salgarkar<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=ngs-sample-preparation-market-growth-outlook-competitive-landscape-future-business-opportunities\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 18886006441<br \/><strong>Address:<\/strong>1615 South Congress Ave.  Suite 103, Delray Beach, FL 33445<br \/><strong>City:<\/strong> Florida<br \/><strong>State:<\/strong> Florida<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/ngs-sample-preparation-market-69735098.html\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.marketsandmarkets.com\/Market-Reports\/ngs-sample-preparation-market-69735098.html<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=ngs-sample-preparation-market-growth-outlook-competitive-landscape-future-business-opportunities\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prominent players in the NGS sample preparation market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), PerkinElmer Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US) Browse 299 market data Tables and 47 Figures spread through 301 &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/ngs-sample-preparation-market-growth-outlook-competitive-landscape-future-business-opportunities_778205.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404,416],"tags":[],"class_list":["post-778205","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/778205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=778205"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/778205\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=778205"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=778205"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=778205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}